Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

Vera Therapeutics (NASDAQ: VERA) said the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy at risk of disease progression. The accelerated approval is a major regulatory milestone that can materially de-risk the program and supports potential future revenue ramp as confirmatory data are pursued.

Analysis

Vera Therapeutics (NASDAQ: VERA) said the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy at risk of disease progression. The accelerated approval is a major regulatory milestone that can materially de-risk the program and supports potential future revenue ramp as confirmatory data are pursued.